Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate;Uticaj polimorfizma gena za AT1 receptor na renoprotektivnu efikasnost losartana kod bolesnika sa dijabetesom tip I i povišenom urinarnom ekskrecijom albumina

Vojnosanitetski Pregled

Volumn 67, Issue 4, 2010, Pages 273-278

  Dragović, Tamara ^a   Ajdinović, Boris ^a   Hrvačević, Rajko ^a   Ilić, Vesna ^a   Magić, Zvonko ^a   Andelković, Zoran ^a   Kocev, Nikola ^b  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Angiotensin II; Diabetes mellitus; Diabetic nephropathies; Genetic; Losartan; Polymorphism; Type 1

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

ADULT; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG TARGETING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RENAL PROTECTION; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; BLOOD PRESSURE; DIABETIC NEPHROPATHY; GENETICS; KIDNEY BLOOD FLOW; PATHOPHYSIOLOGY; URINE;

ADULT; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LOSARTAN; MALE; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL BLOOD FLOW, EFFECTIVE;

EID: 77952975761     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1004273D     Document Type: Article

References (31)

1. Andersen S. Angiotensin II receptor blockade in diabetic nephropathy. Danish Medical Bulletin 2004; 51: 274-94.
2. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27(supp 1): S79-S83.
3. Wolf G. Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant 1999; 14(Supp 1): 42-4.
4. Johnston C. Angiotensin II Type 1 receptor blockade: a novel therapeutic concept. Blood Pressure 2000; 9(Supp 1): 9-13.
5. Jacobsen PK, Tarnow L, Parving HH. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int 2006; 69: 1293-5.
6. Coto E, Marin R, Alvarez V, Praga M, Fernandez Andrade C, Arias M, et al. Pharmacogenetics of angiotensin system in non-diabetic nephropathy. Nefrologia 2005; 25(4): 381-6.
7. Arnett D, Claas S, Glasser A. Pharmacogenetics of hypertensive treatment. Vascular Pharmacology 2006; 44: 107-18.
8. Castellano M, Muiesan ML, Beschi M, Rizzoni D, Cinelli A, Salvetti M, et al. Angiotensin II Type 1 receptor A/C 1166 polymorphism. Hypertension 1996; 28: 1076-80.
9. Baudin B. Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 2004; 90: 277-82.
10. Van Geel PP, Pinto YM, Voors A, Buikema H, Oostrega M, Crijns HJ, et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000; 35: 717-21.
11. Henrion D, Amant C, Benessiano J, Philip I, Plantefeve G, Chatel D, et al. Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro. J Vasc Res 1998; 35: 356-62.
12. Miller J, Thai K, Scholey J. Angiotensin II Type 1 receptor gene polymorphism and the response to hyperglicaemia in early Type 1 diabetes. Diabetes 2000; 49(9):1585-9.
13. Miller J, Thai K, Scholey J. Angiotensin II type 1 receptor gene polymorphism predict response to losartan and angiotensin II. Kidney Int 1999; 56: 2173-80.
14. Andersen S, Tarnow L, Cambien F, Rossing P. Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype? Kidney Int 2002; 62: 192-8.
15. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl T, Deinum J, et al. Long term renoprotective effects of losartan in diabetitic nephropathy. Diabetes Care 2003;26:1501-6.
16. Sacks D, Bruns D, Goldstein D, Maclaren N, McDonald J, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-72.
17. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin coverting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hyperetensive patients. J Hypertens 2001;19:1783-7.
18. Dzida G, Galoziok M, Kraczkowski T, Sobstyl J, Golon-Siekierska P, Puznjak A, et al. C1166 variant of the Angiotensin II receptor type 1 gene and myocardial infarction-risk factor or a chance of survival? Cardiol Pol 2002; 56(2): 138-42.
19. Goates J, Morton K, Whooten W, Greenberg H, Datz F, Handy J, et al. Comparison of the methods for calculating glomerular filtration rate: Technetium-99m-DTPA scintigraphic analysis, protein-free and whole-plama clearance of the technetium99m-DTPA and Iodine-125-iothalamate clearance. J Nucl Med 1990; 31: 424-9.
20. Schlegel JU, Hamway SA. Individual renal plasma flow determination in 2 minutes. J Urol 1976; 116: 282-5.
21. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical and molecular biological correlations. Am J Physiol 1993; 265: 477-86.
22. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACE I to angiotensin II antagonists. Kidney Int 2000; 57: 1803-17.
23. Goa K, Wagstaff A. Losartan potassium. Drugs 1996; 51(5): 820-45.
24. Spiering W, Kroon A, Fuss-Lejeune M, de Leeuw P. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005; 23(4): 753-8.
25. Tuttle KR. Albuminuria reduction: The Holy Grail for kidney protection. Kidney Int 2007; 72: 785-6.
26. Redon J, Luque-Otero M, Martell N, Chaves FJ. Renin-angiotensin system gene polymorphisms:relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. The Pharmacogenomics Journal 2005; 5: 14-20.
27. De Denus S, Zakrzewski-Jakubiak M, Dube MP, Belanger F, Lepage S, Leblanc MH, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008; 42(7): 925-32.
28. Kaidashev IP, Rasin MS, Savchenko LG, Shlykova OA, Iakimishina LI. Clinical efficiency of candesartan depends on angiotensin II receptor, type 1 gene polymorphism. Lik Sprava 2005; 8: 66-71.
29. Lim HS, Cho JY, Oh DS, Chung JY, Hong KS, Bea KS, et al. Angiotensin II type 1 receptor A1166C polymorphism in association with blood pressure response to exogenous angiotensin II. Eur J Clin Pharmacol 2007; 63(1): 17-26.
30. Leehey D, Singh A, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000; 58(Supp 77): S93-8.
31. Schalekamp MADH, Danser AHJ. Angiotensin II production and distribution in the kidney. Model based analysis of experimental data. Kidney Int 2006; 69: 1553-7.